1800-272-662
Shopping Cart 0
countryflagAU
Login

Altimmune Inc

Healthcare US ALT

3.835USD
-0.025(0.65%)

Last update at 2026-03-11T14:55:00Z

Day Range

3.783.91
LowHigh

52 Week Range

5.2814.84
LowHigh

Fundamentals

  • Previous Close 3.86
  • Market Cap685.64M
  • Volume962972
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-99.19100M
  • Revenue TTM0.05M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM -70.52000M
  • Diluted EPS TTM-1.57

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -84.91000M -97.09082M -54.46150M -20.57863M -45.32095M
Minority interest - - - - -
Net income -84.71300M -96.17131M -49.04448M -20.52013M -39.17115M
Selling general administrative 17.13M 15.41M 13.21M 8.50M 9.77M
Selling and marketing expenses - - - - -
Gross profit -0.06800M 4.41M 8.19M 5.80M 10.33M
Reconciled depreciation -0.20500M 0.55M 0.30M 0.39M 0.30M
Ebit -87.74000M -96.91404M -54.79874M -21.46494M -17.38924M
Ebitda -84.90200M -85.71517M -54.15402M -19.21907M -17.08687M
Depreciation and amortization 2.84M 11.20M 0.64M 2.25M 0.30M
Non operating income net other - -0.17113M 0.35M 0.89M -2.18945M
Operating income -87.74000M -96.91404M -54.79874M -21.46494M -42.83441M
Other operating expenses 87.67M 89.95M 62.98M 26.27M 28.22M
Interest expense 0.00800M 0.00566M 0.00942M 0.00224M 0.30M
Tax provision -0.19700M 0.00000M -5.41702M -0.05850M -6.14979M
Interest income 2.87M 0.20M 0.32M 0.84M 0.23M
Net interest income 2.86M 0.20M 0.31M 0.84M -0.07049M
Extraordinary items - - - - -
Non recurring - 11.37M - 1.00M 24.94M
Other items - - - - -
Income tax expense -0.19700M -0.91951M -5.41702M -0.05850M -6.14979M
Total revenue -0.06800M 4.41M 8.19M 5.80M 10.33M
Total operating expenses 87.67M 89.95M 62.98M 26.27M 28.22M
Cost of revenue 0.07M - - - 18.46M
Total other income expense net 2.83M -0.17678M 0.34M 0.89M -27.35673M
Discontinued operations - - - - -
Net income from continuing ops -84.71300M -97.09082M -49.04448M -20.52013M -39.17115M
Net income applicable to common shares -84.71300M -97.09082M -49.04448M -20.97306M -42.47895M
Preferred stock and other adjustments - - - 0.45M 3.31M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 210.64M 206.93M 218.86M 245.12M 54.06M
Intangible assets - 12.42M 12.42M 12.82M 12.73M
Earning assets - - - - -
Other current assets 6.82M 5.36M 13396.50M 1960.85M 504.40M
Total liab 16.54M 21.64M 19.73M 19.24M 8.54M
Total stockholder equity 194.10M 185.29M 199.13M 225.88M 45.52M
Deferred long term liab - - - - -
Other current liab 9.58M 11.80M 6.09M 11.03M 3.58M
Common stock 0.00700M 0.00500M 0.00409M 0.00370M 0.00151M
Capital stock 0.00700M 0.00500M 0.00409M 0.00370M 0.00151M
Retained earnings -466.33100M -377.88400M -293.17142M -186.42060M -137.37612M
Other liab - 3.91M 0.33M 7.22M 3.13M
Good will - - - - -
Other assets 0.00000M 0.02M 0.07M 0.98M 0.13M
Cash 135.16M 111.10M 190.30M 115.92M 8.96M
Cash and equivalents - - - - -
Total current liabilities 12.14M 17.05M 18.28M 12.02M 3.92M
Current deferred revenue 0.00000M - 9.74M 0.02M 0.06M
Net debt -134.48700M -109.97300M -188.76566M -114.09297M -7.21856M
Short term debt 0.50M 0.45M 0.41M 0.36M 0.26M
Short long term debt - - - - -
Short long term debt total 0.67M 1.12M 1.54M 1.82M 1.74M
Other stockholder equity 665.43M 568.40M 497.34M 417.34M 187.91M
Property plant equipment - 1.68M 1.45M 1.06M 1.10M
Total current assets 209.53M 192.81M 204.13M 230.26M 39.39M
Long term investments - - - - -
Net tangible assets - 172.87M 186.72M 213.05M 32.79M
Short term investments 62.70M 73.78M 0.00000M 100.01M 28.28M
Net receivables 4.85M 2.54M 5.84M 12.37M 1.65M
Long term debt - - 1.45M 1.83M 1.86M
Inventory - 0.03M -13388.51614M -1958.88815M -503.89760M
Accounts payable 2.07M 4.80M 2.03M 0.61M 0.02M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -5.00400M -5.22700M -5.04016M -5.04452M -5.02016M
Additional paid in capital - - - - -
Common stock total equity - - 0.00409M 0.00370M 0.00151M
Preferred stock total equity - - - - -
Retained earnings total equity - - -293.17142M -186.42060M -137.37612M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.10M 0.61M 0.87M 0.07M 0.13M
Deferred long term asset charges - - - - -
Non current assets total 1.11M 14.12M 14.74M 14.86M 14.66M
Capital lease obligations 0.67M 1.12M 1.54M 1.82M 1.74M
Long term debt total - - 1.45M 1.83M 1.86M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -73.39900M 99.83M -71.75253M -28.25738M -1.00114M
Change to liabilities 2.77M -0.87717M 7.58M -1.15631M 0.26M
Total cashflows from investing activities -73.39900M 87.52M -72.09495M -28.28638M -1.00114M
Net borrowings - - - -0.29200M -1.54970M
Total cash from financing activities 56.78M 65.10M 213.49M 12.53M 32.49M
Change to operating activities 8.04M -8.20725M 5.62M -0.66868M 1.34M
Net income -84.71300M -97.09082M -49.04448M -20.52013M -39.17115M
Change in cash -79.20400M 74.38M 106.96M -25.35627M 22.05M
Begin period cash flow 190.34M 115.95M 9.00M 34.35M 12.30M
End period cash flow 111.13M 190.33M 115.95M 9.00M 34.35M
Total cash from operating activities -62.58600M -78.23794M -34.43664M -9.60200M -9.38891M
Issuance of capital stock 56.35M 65.04M 172.32M 12.67M 37.40M
Depreciation -0.20500M 0.55M 0.30M 0.39M 0.30M
Other cashflows from investing activities - -0.19454M -0.13846M -0.02777M -0.02574M
Dividends paid - - -135.47100M -3791.48500M 0.02M
Change to inventory - - - -0.28880M 5.59M
Change to account receivables 0.26M 4.18M -3.58902M 2.44M 0.34M
Sale purchase of stock 0.18M 224.47M 135.47M 3791.49M -2.38628M
Other cashflows from financing activities 0.25M -224.41407M 41.80M 0.16M -0.95420M
Change to netincome 8.22M 18.55M 18.82M 8.71M 19.44M
Capital expenditures 0.13M 12.31M 0.34M 0.03M 1.02M
Change receivables - 4.18M -3.58902M 2.44M 0.34M
Cash flows other operating - -3.55472M -8.50501M 0.53M 9.25M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 74.38M 106.96M -25.35627M 22.10M
Change in working capital 14.11M -0.25053M -4.51216M 1.82M 6.98M
Stock based compensation 8.10M 5.52M 2.58M 1.26M 0.77M
Other non cash items 0.12M 0.70M 16.27M 7.51M 27.88M
Free cash flow -62.71200M -90.54959M -34.77906M -9.63100M -10.40454M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALT
Altimmune Inc		 -0.025 0.65% 3.83 - - 13185.41 4.86 9814.20 -4.1998
NVO
Novo Nordisk A/S		 0.16 0.41% 38.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.89 0.98% 494.28 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.71 0.48% 775.75 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune Inc

910 Clopper Road, Gaithersburg, MD, United States, 20878

Key Executives

Name Title Year Born
Dr. Vipin K. Garg Ph.D. Pres, CEO & Director 1958
Mr. Richard I. Eisenstadt M.B.A. Chief Financial Officer 1958
Dr. M. Scot Roberts Ph.D. Chief Scientific Officer 1959
Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS Chief Medical Officer 1953
Mr. Bertrand Georges Ph.D. Chief Technology Officer NA
Mr. Tony Blandin B.S. VP of Quality & Compliance Management NA
Mr. José Ochoa Chief Bus. Officer NA
Mr. Kent A. Tapper BSEE Corp. Controller 1957
Dr. Vipin K. Garg Ph.D. President, CEO & Director 1958
Mr. Raymond M. Jordt M.B.A. Chief Business Officer 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.